• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Cytodyn Inc (OP:CYDY)

    0.3459 -0.0068 (-1.93%)
    Streaming Delayed Price Updated: 3:58 PM EDT, May 19, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Cytodyn Inc

    < Previous 1 2 3 4 5 Next >
    News headline image
    CytoDyn Announces President Takes Medical Leave of Absence
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn to Hold Webcast to Provide a Company Update
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    Trading Volume In The OTCQB Venture Market Picks Up in December – A Summary Of OTC Market Group's Most Active List In December ↗
    On December 14th, the Federal Reserve hiked its key interest rate by 50 basis points. This was the first deceleration in rate hike increases in 2022; between March and November 2022, the interest rate... 
    Via Benzinga
    News headline image
    CytoDyn to Hold Webcast to Discuss the Performance of Leronlimab in Clinical Trials and Recent Charges Against Former CEO
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    OTC Market Group's Most Active List In November: A Dive Into The Names Experiencing Volume Changes ↗
    The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) increased by 5.56% in November, recording two subsequent monthly increases for the first time in 2022. 
    Via Benzinga
    News headline image
    CytoDyn to Host R&D Update on Wednesday, December 7, 2022
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    CytoDyn Announces Voluntary Withdrawal of BLA for HIV-MDR Due to CRO Data Management Issues
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    Most Active On The OTC Markets In September – A Look Back As October Comes To A Close ↗
    The SPDR S&P 500 ETF Trust (NYSEARCA: SPY) declined by 9.62% in September – its largest decline in 2022. 
    Via Benzinga
    News headline image
    CytoDyn Announces Appointment of Additional Directors with Industry Experience
    From CytoDyn Inc.
    Via GlobeNewswire
    News headline image
    OTC Markets' Most Active Securities Sees A Shake-up In July ↗
    July gave world markets a breather from 2022’s poor financial conditions. 
    Via Benzinga
    News headline image
    CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    News headline image
    CYTODYN ALERT: Bragar Eagel & Squire, P.C. is Investigating CytoDyn, Inc. on Behalf of CytoDyn Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire, P.C.
    Via Business Wire
    News headline image
    These 2 Under-The-Radar Stocks Traded More Than $1B Each Last Month ↗
    The month of July saw $37.3 billion in trading volume for stocks that trade on the OTCQK and OTCQB. While some of the stocks that trade over-the-counter are considered penny stocks based on their share... 
    Via Benzinga
    News headline image
    Mortgage Financiers & Crypto Securities Reclaim Their Spots As Most Actively Traded Securities On OTC Markets In June ↗
    Reflecting the expected conditions of a bear market, many of the world’s indices saw a decrease in price throughout June. 
    Via Benzinga
    News headline image
    The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall ↗
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    News headline image
    CYTODYN TECHNOLOGIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of CytoDyn Inc. - CYDY
    From Kahn Swick & Foti, LLC
    Via Business Wire
    News headline image
    These OTC Securities Reported The Most Trading Volume In January – With Possible Sustained Interest In International Operators ↗
    Photo from Jason Briscoe on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
    Via Benzinga
    News headline image
    CytoDyn Announces Leadership Transition Plan to Support Regulatory Approval and Commercialization of Leronlimab
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Cancels Webcast and Live Q/A Scheduled for Today
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Published Paper Indicates Leronlimab Shows Activity Against 4-Class Drug Resistant HIV-1 From Heavily Treatment Experienced (“HTE") Subjects
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Leronlimab 14-Week, NASH Clinical Trial Met Primary Endpoint (PDFF) and Secondary Endpoint (cT1) for Per Protocol Population in 350 mg Weekly Dose
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    Two Paths to End the Pandemic but the Hybrid Approach Looks Dominant ↗
    Pfizer (NYSE: PFE) is arguably one of the biggest leaders in COVID-19 technology, whether it’s their vaccine or their newly approved oral antiviral called Paxlovid. The... 
    Via Benzinga
    News headline image
    CytoDyn Announces Favorable Ruling Granting Injunction Against Former CRO
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Receives Positive Response From FDA in Regard to its Phase 3, Registrational Trial in COVID-19 Critically Ill Population
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    NASH Phase 2 Trial Open-Label Portion Demonstrates Average 80 msec cT1 Reduction in 50% of Patients and Reduction of Nearly 50 msec in 80% of Patients
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Submits Protocol with the FDA for Phase 3 Registrational Trial of Leronlimab for Critically Ill COVID-19 Population
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Files for Expanded Access Use of Leronlimab for Multi-Drug Resistance HIV Patients
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn’s CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn Submits CMC (Manufacturing) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last (Clinical) Section Will Complete Full BLA Submission
    From CytoDyn Inc.
    Via Business Wire
    News headline image
    CytoDyn’s Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow
    From CytoDyn Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.